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Abstract:  
Background: Development of tricuspid regurgitation (TR) after orthotopic heart 
transplantation (OHT) can cause heart failure along with renal and hepatic impairment and 
portends a poor prognosis.  If TR causes significant symptoms, tricuspid valve repair or 
replacement is often required.  This study was designed to study the effects of prophylactic 
tricuspid valve annuloplasty (TVA) during OHT on long-term survival, renal function and amount 
of TR. Methods: Between 4/97 and 3/98, 60 patients (age 18-70, 22 females) randomly 
received either OHT (n=30, group STD) or OHT with DeVega TVA (n=30, group TVA).  TVA 
was performed on the donor heart before implantation using pledgeted 2-0 prolene and sized to 
an annulus of 29mm.  Echocardiographic parameters, lab values and hemodynamics were 
obtained prospectively and reviewed by an independent data analyst.  Results: Follow-up of 
patients up to December 2003  was complete.  Although, there was a peri-operative mortality 
advantage in group TVA, there was no difference in long-term survival.  However, at the end of 
the study period there was a statistical difference (groups STD vs, TVA; p<0.05) with regard to 
cardiac mortality (7/30 vs. 3/30), average amount of TR(1.5±1.3 vs. 0.5±0.4), percentage of 
patients with >2 +TR (34% vs. 0%), serum creatinine (2.9±2.0 vs 1.8±0.7) and difference in 
serum creatinine over baseline (2.0±2.1 vs 0.7±0.8).  Conclusion:  Prophylactic DeVega TVA 
of the donor heart is durable and decreases the incidence of cardiac related mortality and post-
OHT TR.  In addition, there is improved protection of renal function. Considering the ease and 
safety of TVA and its advantages, it should be performed as a routine adjunct to OHT.  
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Introduction:   
Orthotopic heart transplantation (OHT) is often associated with the development of tricuspid 
regurgitation (TR) [1,2] with the reported incidence varying from 47 to 98% [3,4,5].  The TR can 
be related structural or functional factors.  The standard biatrial technique of OHT (sOHT) is 
associated with more TR than the bicaval (bOHT) technique.  This difference is attributed to 
alteration in the geometry of the tricuspid valve and right atrium related to the technique of right 
atrial anastomosis.  Other possible causes of TR include: 1) allograft dysfunction with right 
ventricular dilatation due to poor preservation, reperfusion injury, donor factors, or rejection, 2) 
pulmonary hypertension, 3) severe donor recipient size mismatch, and 4) structural damage 
occurring during endomyocardial biopsy [6,7,8,9,10]. 
Moderate and greater grades of TR are associated with right sided heart failure symptoms, 
renal and hepatic dysfunction, and decreased long-term survival [11, 12].  It remains unclear 
whether the TR is a reflection of poor allograft function or a primary abnormality, but once 
present, repair or replacement is often indicated.   Renal dysfunction is also a long-term 
consequence of OHT.  This is most commonly attributed to the calcineurin inhibitors and may 
also result from TR (13,14,11,ISHLT registry data).  
The DeVega type of tricuspid annuloplasty using a suture has been used to treat TR.  It is 
simple, quick, inexpensive and durable [15,16].  We have previously reported short-term results 
on a population of randomized and prospectively studied patients, one group who received 
prophylactic DeVega TVA to prevent TR after OHT(17).  We demonstrated less TR, improved 
peri-operative heart function and survival.  This paper reports on the long-term (six year) follow-
up of those patients and compares them with regard to survival, amount of TR, renal function 
and hemodynamics.  
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Methods 
Study Design:  
The study design has previously been described (17).  Of the 87 patients receiving heart 
transplants at Temple University Hospital between 4/1997 to 4/1998, 60 patients met selection 
criteria for this comparison.  Institutional Review Board permission was received (3/1997) before 
studying these patients. Twenty-seven patients were excluded because of: 1) multiple organ 
transplantation, 2) re-transplantation, 3) donor/recipient weight ratio <0.5, 4) pulmonary vascular 
resistance (PVR) > 4 woods units, 5) greater than mild TR documented on donor 
echocardiography, 6) donor ejection fraction <35%, 7) donor coronary artery disease requiring 
revascularization, 8) donors requiring two inotropes or dopamine at >12 µg/kg/min.  In 
accordance with our practice at that time, these patients that were deemed higher risk as 
evidenced by one or more of the listed factors, routinely received TVA before the transplant 
procedure.  
Two surgeons performed the procurement and implantation during this time period, and the 
procedures were evenly distributed among them.   TVA was performed during preparation of the 
donor heart.  In order to insure consistency and standardization, only one of the surgeons 
performed the TVA.  By strictly adhering to an evenly distributed procurement call schedule, 
randomization was achieved.  Patients were not included in the comparison if unforeseen 
circumstances caused deviation from the on-call schedule.  In the majority of cases, 
implantation was a combined effort of the two surgeons.  The patients received a OHT (group 
STD) or OHT with TVA (group TVA).  Data were obtained prospectively and data analysts were 
blinded to the assignment of patient groups.  Data analyzed included: operative and donor 
information, survival, amount of TR, hemodynamics, serum BUN and creatinine. 
Procedure:  
University of Wisconsin (Barr Laboratories, Pomona, NY) solution was used for cardioplegia 
and preservation solution.  The recipient cardiectomy and recipient-donor anastomoses were 
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done using the bicaval technique described by Sarsam, et al. [18] and others [19].  All patients 
received a baseline inotropic regiment of T3 (0.08 µg/kg bolus, infusion 0.8 µg/kg for 3 hours), 
5µg/kg/min of dobutamine and 3 µg/kg/min of dopamine.  Any increase above baseline was 
considered as elevated inotropic requirement.  Patients were considered weanable from CPB if 
they could sustain a mean systemic blood pressure >70mmHg with a CVP of <15mmHg and a 
cardiac index (CI)>2.1 L/min/M2 with a combination of inotropic and IABP support.   
Group TVA patients received a DeVega type annuloplasty on the donor graft prior to 
implantation.  The tricuspid valve was visualized through the inferior caval or right atrial opening 
and a double layer of pledgeted 2-0 polypropylene was used to stabilize the annulus.  The 
annulus was sized to a 29mm dilator.  If the annulus was less than 29mm, it was stabilized to a 
size just a little smaller than the native annulus.  
Management:  
All patients received triple-drug immunnosuppression therapy with cyclosporine (CyA) (3.5-5.0 
mg/kg/day), azathioprine (1.5-2.5 mg/kg/day) and steroids.  Induction therapy was not routinely 
used.  Patients either had the CyA switched to tacrolimus or had mycophenolate mofetill 
substituted for azathioprine for repeated rejection. CyA therapy was adjusted to maintain serum 
trough levels of 250 to 300 ng/ml during the first year after HT.  Azathioprine dose was adjusted 
to maintain white blood cell counts >4,000/ml.  Steroid dose was tapered gradually after the 
peri-transplant period to 0.05 mg/kg within six months after surgery. Acute rejection (>1b or with 
hemodynamic compromise) was treated with a steroid bolus.  Cytolytic therapy was added for 
repeated rejections or significant hemodynamic compromise.  Endomyocardial biopsy was 
performed using the standard Stanford technique with either a Caves-Shultz or disposable 
bioptome[20].  Biopsy-proven rejection was graded using the modified Billingham system 
adopted by the International Society for Heart and Lung Transplantation [21]. 
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Echocardiographic assessment of TR 
Patients routinely underwent intra-operative transesophageal echocardiography (TEE), and 
then transthoracic (TTE) studies at one week, one month, and then annually.  As part of the 
echocardiographic studes, patients received two-dimensional and continuous-wave Doppler 
evaluation with color flow mapping.  The tricuspid valve was examined in the parasternal short-
axis and apical four-chamber views.  Tricuspid regurgitation was graded by qualitative 
echocardiographic assessment according to the ratio of the regurgitant jet area to the right atrial 
area, as described previously [18].  Grades of TR included: 0, 1+ (jet to area ratio <10%,trace), 
2+ (ratio 10-24%, mild), 3+ (ratio 25-49%, moderate), 4+ (ratio >50%, severe).   Multiple views 
were obtained and the regurgitation graded based upon the most abnormal views.   
Hemodynamic Assessment 
Intra-operative pulmonary artery monitoring with a Swan-Ganz catheter was performed in 
every patient.  Right heart catheterization was routinely performed with biopsy at one week, one 
month, and annually, or if dictated by clinical condition.  Intra-cardiac pressures were recorded 
at the levels of the right atrium, right ventricular body, and pulmonary artery.  Thermodiluton 
cardiac outputs were also obtained.  
Statistics 
All numerical results are reported as mean ± standard deviation. A p value of less than 0.05 was 
considered to be significant. Statistical analysis was performed using SPSS v.11 (SPSS Inc, 
Chicago, IL). Fisher's exact test was applied for associations of categorical variables, and the 
Wilcoxon rank sum test was used to compare means of continuous variables. Survival analysis 
was performed using the log rank statistic. 
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Results: 
General Characteristics:  There were 30 patients in each group.  Recipient and donor 
demographics are presented in tables 1 and 2 respectively.  Pre-transplant pulmonary artery 
pressures were similar in both groups (STD vs. TVA, p=ns: mPAP 28.6±9.2 vs. 29.3±8.9; 
PCWP 23.2±8.9 vs. 23.8±9.0; PVR Woods units 2.3±0.9 vs. 2.1±1.1).  The two surgeons who 
performed the procedures were randomly distributed among the procurement and implantation 
groups, based on the call schedule.  Both groups followed the same routine myocardial biopsy 
schedule.  The average number of biopsies for the first year in survivors of both groups was 
15.2. After the first year, patients received routine biopsies bi-annually unless clinically 
indicated.  None of the patients required a permanent pacemaker.  There was no incidence of 
tricuspid stenosis. 
Tricuspid regurgitation:  The average amount of TR in each group was stable during the 
study period.  TEE evaluation of patients after weaning from CPB and stabilization revealed 
more TR in group STD (table 3).  The difference in average TR  persisted at one and six years.  
Moreover, the standard group had a greater incidence of >2+ TR.  Subsequently, there was a 
progressive increase in the number of patients with grade ≥3+ TR in group STD.  Group TVA 
had a stable distribution of TR severity.  No patients in group TVA developed significant TR 
(≥2+).  By six years, three patients in group STD demonstrated clinical signs of TR with 
peripheral edema and increased diuretic requirements.  Two required a tricuspid valve 
procedure.  There is a significant correlation between TR≥2+ and mortality as well as TR and 
increase in creatinine (figures 1 and 2).   
Hemodynamics:  The hemodynamic values (table 4) at one and six years were similar. 
Renal function:  The BUN was similar in the two groups.  The baseline creatinine in group 
TVA seems higher in group STD (1.34±0.67 vs 1.02±0.29), but it fails to attain significance.  The 
serum creatinine increased in both groups after transplant, and continued to increase in group 
STD while stabilizing in group TVA.  Serum creatinine and the difference in creatinine from 
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baseline were significantly higher in group STD at 6 years (table 5).  In the overall population of 
patients, there is a correlation between creatinine ≥2+ and mortality (figure. 3) 
Morbidity and Mortality:  Overall survival among both groups was similar with 8 patients 
expiring in both groups.  Group STD had a higher intra-operative mortality (4/30 vs 0/30).  Three 
deaths were due primarily to right heart failure and one to an acute rejection. Although, the 
patients eventually died of multiple system organ failure, the root cause was low cardiac output.  
By the first and sixth years, survival was similar between groups (table 7). Of note, 7/8 deaths in 
Group STD were cardiac in origin.  One patient died of a malignancy.  In group TVA, there were 
3 cardiac deaths, two perforated visceral organs and 3 infections.  There were statistically more 
cardiac related deaths in group STD (p=0.03).  The average number of treated rejection 
episodes per patient was similar between groups. 
 
Comment: 
Tricuspid regurgitation frequently develops following OHT and can be progressive [11].  
Variability exists between the common techniques for measuring TR [5].  The color doppler 
quantification method is the one used in this study and is the technique that is most widely 
accepted(4). Using this technique, Huddleston et al. found that 21% had greater than moderate 
TR [3].  Williams et al. found a 32% prevalence of moderate to severe TR following heart 
transplantation [23].  Aziz et al. found that 36% of patients developed greater than moderate TR 
after OHT [11].  In the largest study to date, the Stanford group analyzed 336 patients and found 
34% had greater than moderate TR. In addition, the studies that follow patients over a period of 
time demonstrate the progressive nature of this abnormality.  For instance, in the Stanford 
experience, the incidence of severe TR increases in survivors from 7.8% at five years to 14.2% 
at ten years [5].  
TR can become a serious condition.  If the TR progresses past moderate, a majority of 
patients can develop peripheral edema, ascites and renal dysfunction.  Furthermore, the long 
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term survival in patients with moderate TR is decreased when compared to patients with less 
than mild TR [11,5].  In a study analyzing intra-operative echocardiograms, immediate 
significant TR was associated with a poor long term survival.  The authors suggest a role for 
concomitant TVA at the time of transplant [12].   
When severe TR is present, repair with an annuloplasty or replacement has been reported 
[2,24].  DeVega tricuspid annuloplasty is an inexpensive, quick and stable method to reduce a 
dilated annulus.  It has been primarily used to treat functional TR caused by elevated left sided 
pressures with excellent long term results [15,16].  This study defined the role of prophylactic 
TVA.  Whether the TVA is best accomplished by a DeVega technique or by a ring is based on 
surgeon preference.  Stabilization with an annuloplasty ring is preferable in patients with severe 
TR and dilatation of the annulus.  However, in this study, none of the patients had an 
abnormally dilated annulus.  The DeVega annuloplasty was performed to maintain the normal 
size of the annulus.  This was clearly accomplished in the study as there was no progression or 
development of new TR in group TVA.  The technique employed in the performance of the 
DeVega annuloplasty is important: careful and closely spaced sutures with a double pledgeted 
repair is critical in maintaining the integrity of the annulus.  We have used an annuloplasty ring 
in other patients but have found the bulky prosthetic material to be a hindrance for biopsies, 
which makes these procedures time consuming and expensive.  Complications of the TVA are 
uncommon, and are primarily related to injury of the conduction system.  It is also important not 
to create stenosis by reducing the annulus excessively.  Tricuspid stenosis or heart block did 
not occur in any patient. 
TR following OHT is often a complication of the endomyocardial biopsy procedure 
[23,25,26,27].  Many studies correlate the presence of flail leaflets and torn chordae with severe 
TR.  In fact, almost all reported cases of TV repair or replacement after OHT have demonstrated 
mechanical disruption of the TV.  There is no reason to believe that a TVA would prevent 
mechanical disruption of the valve mechanism.  However, since the annulus is decreased, TR 
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from minor structural damage can be attenuated.  Two patients in group TVA had biopsy proven 
injury to the chordal structures.  Subsequent echocardiograms confirmed ruptured chorde.  
However, the TR did not increase above a mild degree.   
Other causes of TR have a functional basis.  The presence of pulmonary hypertension may 
cause right ventricular and annular dilatation causing TR.  One study demonstrated a correlation 
between pulmonary hypertension and TR.  However, several other studies have shown no 
correlation between pre- or post-operative recipient pulmonary hypertension and development 
of severe TR [23,7,9].  Pulmonary hypertension by itself with a normal RV appears to be well 
tolerated; superimposition of pulmonary injury or RV dysfunction may contribute to a process 
leading to development of TR.  RV dysfunction can be caused in the intra-operative period by 
preservation or reperfusion injury, air embolus, donor risk factors, or accelerated rejection.  The 
short term results of this study (17) demonstrated improved peri-operative survival, especially 
when these stresses were imposed on a donor organ.  Long-term, there was a decrease in 
cardiac associated mortality.  If a cardiac related stress is superimposed on a transplant patient, 
the TVA allows of maintenance of myocardial efficiency, lower CVP and perhaps enough 
restoration of perfusion to allow these patients to survive.  However, OHT is associated with 
many factors that can cause death, such as infection and malignancy.  Hence, despite being 
superior with regard to intra-operative and cardiac survival, the overall mortality in both groups 
was similar.  
We exclusively used a bicaval technique for OHT.  There is ample evidence that bicaval OHT 
is superior to standard biatrial OHT in preventing TR.  This is attributed to elimination of the 
RA/RV relationship caused by the biatrial implantation technique.  In a study of 249 patients, 
Aziz et al. report a 19.9% incidence of severe TR in the bOHT group as opposed to 51% for the 
sOHT group[11].  Since there was evidence that bicaval OHT decreases TR and improves sinus 
node function [28,29], we used this technique for all patients.  If the standard OHT technique 
had been utilized, the prophylactic TVA might theoretically be of additional benefit. 
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We tested the hypothesis that prophylactic TVA, done before OHT, could impact the incidence 
of TR, the need for further TV procedures and patient outcomes.  This was a single center study 
and was, therefore, small.  Two surgeons were responsible for all the transplant procedures.  It 
was important not to alter normal practice, while standardizing the TVA and removing surgeon 
variability as a confounding factor in the comparison.  Therefore only one surgeon performed 
the TVA.  Randomization was ensured by strictly following an evenly distributed on-call 
schedule.  Implantation was also evenly distributed among the two surgeons.  Of the sixty 
implantation procedures, 45 were a combined effort of the surgeons.  There was no correlation 
between surgeon and intra-operative complications.  This study could not be blinded to the 
surgeon.  Data analysts were blinded as much as possible, but in a majority of cases, the 
pledgets of the TVA were evident on TEE or TTE as an echo density. 
The pre-transplant status of recipients and donors were similar in both groups.  The significant 
differences at long-term follow-up included prevention of significant TR and renal protection.  
The amount of TR was low, as would be expected from the bicaval technique, but was still 
different among the groups.  In the early peri-transplant period, group STD had a mean of 1.1 vs 
group TVA .33 TR.  This is represented as a mean of only mild TR, but there was increased 
mortality in the patients who developed greater than moderate TR (17).  Group TVA patients 
had only trivial TR; even the patients with myocardial dysfunction developed only mild TR.  The 
difference in average TR continues to be present at one and six years of follow-up.   
Furthermore, in group STD, the percentage of patients with ≥ 2+ TR remains stable at ~30% 
throughout the study period.  The incidence of moderate/severe TR (>3+) in group STD is 7.6% 
at one year and compares favorably to other reports using bOHT techniques.  At six years, the 
severe TR group increases to 22.7% of the survivors.  At one and six years, there were no 
patients with greater than mild TR in group TVA.  Three patients in group STD developed 
clinical symptoms from central venous hypertension.  Two required operative correction.  It is 
evident from other reports that TR is progressive and can lead to worsening right heart failure 
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symptoms.  That is consistent with the STD group in this study.  Furthermore, follow-up of 
patients in this study demonstrates that a TVA prevents development and progression of TR.  
The other parameter which we studied was renal function, since there are data to correlate 
renal dysfunction with worsening TR[11,12,13].  Increased CVP in patients with TR contributes 
to increased renal venous pressure, which has been shown to be responsible for decreased 
renal artery flow.  This in turn increases plasma rennin activity, causes urinary protein leak, and 
decreases glomerular filtration rate.  This explains the deterioration in renal function in patients 
with significant TR [11].  In this study, patients’ serum creatinine progressively increased during 
the first year in both groups.   However, by 6 years, there is stabilization of renal function in 
group TVA and the different average levels of serum creatinine and the difference from baseline 
from group STD are significant.  Furthermore, there is significant correlation between 
development of increased creatinine and mortality.  Calceneurin inhibitors can contribute to 
renal dysfunction and that effect is present in both groups.  However, the development of TR is 
an added insult and correlates with renal dysfunction.  This effect is evident only after long-term 
follow-up and the development of moderate TR with deterioration in renal function.   
There were several limitations for this study.  Since it was a single center study, it was 
relatively small.  The study could not be properly blinded due to the performance of a surgical 
procedure in the OR and the visibility of the TVA on echocardiography.  One could argue that 
both surgeons should have performed the TVA.  We felt that since this was a small study, it was 
important to remove any variability in the TVA technique and standardize the procedure.  If this 
was a larger study, involvement of other surgeons would have decreased some of the 
variability.  The study was also conducted prior to approved use of nitric oxide and expanded 
use of mechanical devices to support the right ventricle.  It is possible that the mortality benefit 
might have decreased with routine early use of a right ventricular assist device such as the 
Abiomed BVS 5000 (Abiomed, Danvers, MA).  
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In summary, this is the first long-term report of using prophylactic TVA to decrease TR after 
OHT.  Previous reports using this patient population demonstrated survival benefit to TVA in the 
immediate post-operative period.  This is the period of time when the heart is maximally 
stressed and the patients are vulnerable to the effects of a low perfusion state.  This cardiac 
protective effect is present long-term as demonstrated by less cardiac related deaths.  However, 
the overall survival is similar.  The study also demonstrates significant reduction in the mean 
severity and number of patients with significant TR.  This prevention of TR has important long 
term beneficial effect as the presence of moderate TR is progressive and associate with a poor 
prognosis.   Since there is correlation between development of TR and renal dysfunction, the 
TVA helps preserve renal function.  Prophylactic DeVega TVA is inexpensive, quick to perform, 
durable at one year, and offers a survival advantage in the immediate post operative period.   
Long-term, there is better preservation of renal function and prevention of TR.  Since TVA is 
beneficial, it should be routinely considered during preparation of a donor heart for 
transplantation.   
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Table 1 - Recipient Demographics 
         
Group Age M/F Height(cm) Weight(kg) Cause UNOS Mech Reop 
STD 53.1 ± 12.2 18/12 169.2 ± 12.7 80 ± 12.7 Ish 13 I  27 5 12 
     Idio 16 II  3   
     PP 1    
         
TVA 51.1 ± 11.7 20/10 172.2 ± 10.7 79.5 ± 18.7 Ish 13 I  26 5 13 
     Idio 17 II  4   
     PP 0    
 ns ns ns ns   ns ns 
         
M/F: male/female        
Cause: Ish - ischemic; Idio - idiopathic; PP - postpartum     
UNOS: United Network of Organ Sharing listing status     
Mech: mechanical assistance including LVAD or IABP     
Reop: previous sternotomy       
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Table 2 - Donor Demographics 
      
Group Age M/F Height(cm)  Wt(kg) D/R ratio 
STD 26 ± 13.1 22/8 161 ± 35.9 65 ± 19.5 0.8 ± 0.2 
      
TVA 26.9 ± 12.6 19/11 167.5 ± 16.2 67.5 ± 19.5 0.8 ± 0.2 
 ns ns ns ns ns 
      
D/R ratio: ratio of donor/recipient weight   
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Table 3 - Distribution of the severity TR   
  
 
     
 Group Avg. ≤ 1 2 
≥ 
3 % > 2 % ≥3 
Intra-operative STD 1.1 ± 1.0 21 5 4 30.0% 13.3% 
 TVA .33 ± .38 30 0 0 0.0% 0.0% 
  p=0.01    p=0.01 P=0.002 
        
1 Year STD  1.3 ± 1.0 17 7 2 34.6% 7.6% 
 TVA 0.2 ± 0.3 27 0 0 0.0% 0.0% 
  p=0.01    p=0.02 P=0.01 
        
6 Year STD  1.5 ± 1.3 15 2 5 31.8% 22.7% 
 TVA 0.5 ± 0.4 22 0 0 0.0% 0.0% 
  p=0.01    p=0.01 P=0.005 
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Table 4 - Hemodynamic measurements 
       
 Group mSys mPA CVP mPA-CVP CI 
1 Year STD 82.1±10.7 19.1 ± 9.2 6.5 ± 4.3 13.4 ± 6.5 3.6 ± .7 
 TVA 87.3±9.8 20.4 ± 9.1 6.9 ± 4.9 14.3 ± 6.32 3.3 ± .6 
   ns ns ns ns 
       
6 year STD 
84.2±12.1 
23 ± 5.2 4.4 ± 3.2 15 ± 3.2 2.8 ± .5 
 TVA 82.6±11.8 22.2 ± 6.7 7.8 ± 4.4 14.5 ± 4.2 2.9 ± .5 
  ns ns ns ns ns 
mSys(mmHg): mean systemic blood pressure    
mPA(mmHg): mean pulmonary artery pressure    
CVP(mmHg): central venous pressure    
CI(L/min/m2): cardiac index     
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Table 5 - Renal function following heart transplantation 
     
 Group BUN Crt dCrt 
Pre-operative STD 22.3 ± 11.5 1.02 ± .3  
 TVA 26.8 ± 15.6 1.34 ± .7  
  ns p=0.058  
     
1 Year STD 42.5 ± 16.5 2.3 ± 1.3 1.3 ± .9 
 TVA 37.7 ± 15 2.2 ± 1 1.0 ± .9 
  ns ns p=0.061 
     
6 Year STD 41.0 ± 14.4 2.9 ± 2.0 2.0 ± 2.1 
 TVA 32.1 ± 12.1 1.8 ± 0.7 0.7 ± .8 
  ns P=0.01 p=0.005 
     
BUN(mg/dl): blood urea nitrogen     
Crt (mg/dl): serum creatinine     
dCrt: difference in creatinine from 
baseline  
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Table 7 - Complications and mortality following heart transplantation 
     
Group Intra-operative Mortality Mortality Cardiac 
  complications 1 year 6 year deaths 
A Bleeding  3 RHF  3 CHF  3 7 
 Pul HTN/RHF  5 rejection  1 cancer  1  
 CVA  1    
 Pulm hem  1    
 Donor dys  2    
     
B Bleeding  3 1 rejection CHF 2 3 
 Pul HTN/RHF  4 1 sepsis 
Perforated 
bowel 2  
 Donor dys  3 1 pneumonia Pneumonia 1  
  ns ns P=0.03 
     
Pul HTN - pulmonary hypertension 
RHF -  right heart failure  
CVA - cerebral vascular accident   
Pulm hem - pulmonary hemorrhage   
Donor dys - biventricular donor 
dysfunction 
CHF – allograft failure  
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Figure 1: Survival in patients with tricuspid regurgitation ≥2+ 
 
Figure 2: Linear regression showing correlation between tricuspid regurgitation and elevation in 
serum creatinine  
 
Figure 3: Survival in patients with elevation is serum creatinine ≥ 2.5 mg/dl 



